Brokerage firm PiperJaffray Downgrades its rating on Ultragenyx Pharmaceutical Inc(RARE). The shares have been rated Neutral. Previously, the analysts had a Overweight rating on the shares. The rating by the stock financial advisor at PiperJaffray was issued on Mar 23, 2017 in a research report to their Investors and Clients.
In a different note, On Mar 23, 2017, Wedbush said it Reiterates its rating on Ultragenyx Pharmaceutical Inc. According to the research note, Wedbush Lowers the price target to $80 per share from a prior target of $88. The shares have been rated ‘Outperform’ by the firm.
Ultragenyx Pharmaceutical Inc (RARE) shares turned negative on Fridays trading session with the shares closing down -1.67 points or -2.32% at a volume of 13,76,799. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $72.38. The peak price level was also seen at $72.38 while the days lowest was $67.9101. Finally the shares closed at $70.32. The 52-week high of the shares is $91.345 while the 52-week low is $46.52. According to the latest information available, the market cap of the company is $2,934 M.
Ultragenyx Pharmaceutical Inc(RARE) last announced its earnings results on Feb 16, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $5.000K. Analysts had an estimated revenue of $70.000K. Earnings per share were $-1.75. Analysts had estimated an EPS of $-1.72.
Several Insider Transactions has been reported to the SEC. On Mar 10, 2017, Theodore Alan Huizenga (Controller and PAO) sold 2,500 shares at $86.34 per share price.Also, On Mar 3, 2017, Shalini Sharp (CFO & Executive Vice President) sold 12,000 shares at $90.10 per share price.On Nov 17, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $81.39 per share price, according to the Form-4 filing with the securities and exchange commission.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).